Ernexa Therapeutics (ERNAW) FCF Payout Ratio (2016 - 2023)

Ernexa Therapeutics has reported FCF Payout Ratio for 8 years, with the latest figure at 0.0 in Q4 2023.

• For the quarter ending Q4 2023, FCF Payout Ratio fell 16.58% year-over-year to 0.0; the trailing twelve-month figure through Sep 2024 stood at 0.0 (down 22.28% YoY), and the FY2023 full-year result was 0.0, down 4.14% from the prior year.
• FCF Payout Ratio for Q4 2023 stood at 0.0, down from 0.0 in the prior quarter.
• The five-year high for FCF Payout Ratio was 0.01 in Q4 2019, with the low at 0.0 in Q4 2023.
• Historically, FCF Payout Ratio has averaged 0.0 across 5 years, with a median of 0.0 in 2021.
• Annual changes were most pronounced in 2022 — FCF Payout Ratio plunged 390.84% — and 2023, when it declined 16.58%.
• Ernexa Therapeutics' FCF Payout Ratio stood at 0.01 in 2019, then slumped by 46.38% to 0.0 in 2020, then slumped by 89.43% to 0.0 in 2021, then tumbled by 390.84% to 0.0 in 2022, then fell by 16.58% to 0.0 in 2023.
• The last three FCF Payout Ratio figures came in at 0.0 (Q4 2023), 0.0 (Q4 2022), and 0.0 (Q4 2021), per Business Quant data.